The most important radiopharmaceutical in the diagnosis of dementia is (18F) 2'-fluoro-2'-
deoxy-D-glucose (FDG). Its distribution is assessed using a combined PET/CT scanner (Fig …

18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) is a powerful
method for detection of disease-related impairment of cerebral glucose metabolism in …

Since the invention of 18 F-FDG as a neurochemical tracer in the 1970s, 18 F-FDG PET has
been used extensively for dementia research and clinical applications. FDG, a glucose …

A. The document considers the work of previous guideline organizations such as the
German Inter Disciplinary Consensus Conference on Clinical Brain PET, The Austrian …

Around 1975, positron emission tomography (PET) was used for the first time toimage brain
function (1). It remained primarily a research tool for the next 20 years, until its cost …

With the widespread use of 18F-FDG in oncology, it is easy to forget that 18F-FDG evolved
from the seminal work of Louis Sokoloff et al.(2) to measure regional cerebral glucose …

Glucose is the main metabolic substrate of the brain and its oxidation produces the amount
of energy that is necessary for adequate cerebral activity. The PET tracer 18F …

Increases and decreases of synaptic activity in the brain are accompanied by proportional
changes in capillary perfusion and local glucose consumption. These changes in glucose …

Brain PET imaging with [F-18] fluorodeoxyglucose (FDG) has been used extensively for
research and clinical applications in dementia. Since the invention of FDG in the 1970s and …

PET/CT is an important molecular imaging technique for the assessment of neurological
disorders. The most widely used radiopharmaceutical for both clinical and research …